Prospective clinical randomized controlled trial on the safety and efficacy of novel coronavirus oral antiviral polypeptide LL-37 preparation

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2022
INTERVENTION: B:Lactococcus Lactis;A: antiviral polypeptide LL‐37 preparation; CONDITION: novel coronavirus pneumonia PRIMARY OUTCOME: nuclear acid test of the upper respiratory tract;CT test of lung;nuclear acid test of stool; INCLUSION CRITERIA: (1) all patients with clearly diagnosed novel coronavirus pneumonia who voluntarily receive treatment and do not participate in other clinical trials; (2) aged >=18 years, approved by the ethics committee, fully understand and sign the informed consent.
Epistemonikos ID: 93511917627cee2a4e2896f50ca230fc35a677a7
First added on: Sep 15, 2022